Regional deposition of mometasone furoate nasal spray suspension in humans

Allergy and Asthma Proceedings

Volumn 36, Issue 1, 2015, Pages 48-57

  Shah, Samir A ^a   Berger, Robert L ^a   McDermott, John ^b   Gupta, Pranav ^a   Monteith, David ^a   Connor, Alyson ^b   Lin, Wu ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Quotient Clinical   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MOMETASONE FUROATE; NOSE SPRAY; PENTETATE TECHNETIUM TC 99M; ANTIALLERGIC AGENT; PREGNANE DERIVATIVE;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; FEMALE; GAMMA CAMERA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; ISOTOPE LABELING; MALE; MUCOCILIARY CLEARANCE; NEBULIZER; NOSE CAVITY; NUCLEAR MAGNETIC RESONANCE IMAGING; SUSPENSION; CHEMISTRY; MEDICINAL CHEMISTRY; MIDDLE AGED; SCINTISCANNING; YOUNG ADULT;

ADULT; ANTI-ALLERGIC AGENTS; CHEMISTRY, PHARMACEUTICAL; FEMALE; HUMANS; ISOTOPE LABELING; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MUCOCILIARY CLEARANCE; NASAL SPRAYS; PREGNADIENEDIOLS; RADIONUCLIDE IMAGING; YOUNG ADULT;

EID: 84919767000     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2015.36.3817     Document Type: Article

References (55)

1. Laube BL. Devices for aerosol delivery to treat sinusitis. J Aerosol Med 20:S5-S17; discussion S17-S18, 2007.
2. Newman SP, Pitcairn GR, and Dalby RN. Drug delivery to the nasal cavity: In vitro and in vivo assessment. Crit Rev Ther Drug Carrier Syst 21:21-66, 2004.
3. Ruppar D. Sniffing out new sources of growth. Drug Deliv Technol 6:30-33, 2006.
4. Vidgren MT, and Kublik H. Nasal delivery systems and their effect on deposition and absorption. Adv Drug Deliv Rev 29: 157-177, 1998.
5. Ugwoke MI, Verbeke N, and Kinget R. The biopharmaceutical aspects of nasal mucoadhesive drug delivery. J Pharm Pharmacol 53:3-21, 2001.
6. Skretting A, and Djupesland PG. A new method for scintigraphic quantification of deposition and clearance in anatomical regions of the human nose. Nucl Med Commun 30:629-638, 2009.
7. Hochhaus G, Sahasranaman S, Derendorf H, Mollmann H. Intranasal glucocorticoid delivery: Competition between local and systemic effects. STP Pharm Sci 12:23-31, 2002.
8. Kimbell JS, Segal RA, Asgharian B, et al. Characterization of deposition from nasal spray devices using a computational fluid dynamics model of the human nasal passages. J Aerosol Med 20:59-74, 2007.
9. Charlton S, Jones NS, Davis SS, and Illum L. Distribution and clearance of bioadhesive formulations from the olfactory region in man: Effect of polymer type and nasal delivery device. Eur J Pharm Sci 30:295-302, 2007.
10. Hardy JG, Lee SW, and Wilson CG. Intranasal drug delivery by spray and drops. J Pharm Pharmacol 37:294-297, 1985.
11. Newman SP, Morén F, and Clarke SW. Deposition pattern from a nasal pump spray. Rhinology 25:77-82, 1987.
12. Suman JD, Laube BL, and Dalby R. Comparison of nasal deposition and clearance of aerosol generated by nebulizer and an aqueous spray pump. Pharm Res 16:1648-1652, 1999.
13. Bergstrom M, Cass LM, Valind S, et al. Deposition and disposition of [11C]zanamivir following administration as an intranasal spray. Evaluation with positron emission tomography. Clin Pharmacokinet 36(Suppl. 1):33-39, 1999.
14. Harris AS, Svensson E, Wagner ZG, et al. Effect of viscosity on particle size, deposition, and clearance of nasal delivery systems containing desmopressin. J Pharm Sci 77:405-408, 1988.
15. Djupesland PG, Skretting A, Winderen M, and Holand T. Breath actuated device improves delivery to target sites beyond the nasal valve. Laryngoscope 116:466-472, 2006.
16. Pennington AK, Ratcliffe JH, Wilson CG, and Hardy JG. The influence of solution viscosity on nasal spray deposition and clearance. Int J Pharm 43:221-224, 1988.
17. Hochhaus G, González MA, Dockhorn RJ, et al. A new solution-based intranasal triamcinolone acetonide formulation in patients with perennial allergic rhinitis: how does the pharmacokinetic/pharmacodynamic profile for cortisol suppression compare with an aqueous suspension-based formulation? J Clin Pharmacol 42:662-669, 2002.
18. Merkus FW, Verhoef JC, Schipper NG, and Marttin E. Nasal mucociliary clearance as a factor in nasal drug delivery. Adv Drug Deliv Rev 29:13-38, 1998.
19. Möller W, Schuschnig U, Khadem Saba G, et al. Pulsating aerosols for drug delivery to the sinuses in healthy volunteers. Otolaryngol Head Neck Surg 142:382-388, 2010.
20. Mao S, Chen J, Wei Z, et al. Intranasal administration of mela-tonin starch microspheres. Int J Pharm 272:37-43, 2004.
21. Naclerio RM, Baroody FM, Bidani N, et al. A comparison of nasal clearance after treatment of perennial allergic rhinitis with budesonide and mometasone. Otolaryngol Head Neck Surg 128:220-227, 2003.
22. Bacon R, Newman S, Rankin L, et al. Pulmonary and nasal deposition of ketorolac tromethamine solution (SPRIX) following intranasal administration. Int J Pharm 431:39-44, 2012.
23. Onrust SV, and Lamb HM. Mometasone furoate. A review of its intranasal use in allergic rhinitis. Drugs 56:725-745, 1998.
24. Davies RJ, Bagnall AC, Mccabe RN, et al. Antihistamines: topical vs oral administration. Clin Exp Allergy 26(Suppl. 3):11-17,1996.
25. Unite States Food and Drug Administration. Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products - Chemistry, Manufacturing, and Controls Documentation. Washington, DC: United States Food and Drug Administration; 2002.
26. Suman JD, Laube BL, and Dalby R Validity of in vitro tests on aqueous spray pumps as surrogates for nasal deposition, absorption, and biologic response. J Aerosol Med 19:510-521, 2006.
27. Shah K, Needham T, Beihn R, et al. An evaluation of nasal spray deposition and clearance in healthy human volunteers using γ scintography. Drug Deliv Technol 5:2005.
28. García Arieta A. Validity of in vitro tests on aqueous spray pumps as surrogates for nasal deposition, absorption, and biologic response. J Aerosol Med 20:361-362; author reply 363-364,2007.
29. Hallworth GW, and Padfield JM. A comparison of the regional deposition in a model nose of a drug discharged from metered aerosol and metered-pump nasal delivery systems. J Allergy Clin Immunol 77:348-353, 1986.
30. Berger WE, Godfrey JW, and Slater AL. Intranasal corticosteroids: the development of a drug delivery device for fluticasone furoate as a potential step toward improved compliance. Expert Opin Drug Deliv 4:689-701, 2007.
31. Garcia GJ, Tewksbury EW, Wong BA, and Kimbell JS. Interindividual variability in nasal filtration as a function of nasal cavity geometry. J Aerosol Med Pulm Drug Deliv 22:139-155, 2009.
32. Schroeter JD, Tewksbury EW, Wong BA, and Kimbell JS. Experimental measurements and computational predictions of regional particle deposition in a sectional nasal model. J Aerosol Med Pulm Drug Deliv Epub ahead of print February 28, 2014. doi: 10.1089/jamp.2013.1084.
33. Mygind N, and Vesterhauge S. Aerosol distribution in the nose. Rhinology 16:79-88, 1978.
34. Cheng YS, Holmes TD, Gao J, et al. Characterization of nasal spray pumps and deposition pattern in a replica of the human nasal airway. J Aerosol Med 14:267-280, 2001.
35. Foo MY, Cheng YS, Su WC, and Donovan MD. The influence of spray properties on intranasal deposition. J Aerosol Med 20: 495-508, 2007.
36. Hughes R, Watterson J, Dickens C, et al. Development of a nasal cast model to test medicinal nasal devices. Proc Inst Mech Eng H 222:1013-1022, 2008.
37. Kundoor V, and Dalby RN. Assessment of nasal spray deposition pattern in a silicone human nose model using a color-based method. Pharm Res 27:30-36, 2010.
38. Kaye RS, Purewal TS, and Alpar OH. Development and testing of particulate formulations for the nasal delivery of antibodies. J Control Release 135:127-135, 2009.
39. Berridge MS, Lee Z, and Heald DL. Regional distribution and kinetics of inhaled pharmaceuticals. Curr Pharm Des 6:1631-1651, 2000.
40. Newman SP. Characteristics of radiolabelled versus unlabelled inhaler formulations. J Aerosol Med 9(Suppl. 1):S37-S47, 1996.
41. Devadason SG, Chan HK, Haeussermann S, et al. Validation of radiolabeling of drug formulations for aerosol deposition assessment of orally inhaled products. J Aerosol Med Pulm Drug Deliv 25(Suppl. 1):S6-S9, 2012.
42. Vidgren P, Vidgren M, Paronen P, et al. Nasal distribution of radioactive drug administered using two dosage forms. Eur J Drug Metab Pharmacokinet Spec No 3:426-432, 1991.
43. Aoki FY, and Crowley JC. Distribution and removal of human serum albumin-technetium 99m instilled intranasally. Br J Clin Pharmacol 3:869-878, 1976.
44. Newman SP, Steed KP, Hardy JG, et al. The distribution of an intranasal insulin formulation in healthy volunteers: effect of different administration techniques. J Pharm Pharmacol 46:657-660,1994.
45. McInnes FJ, O'Mahony B, Lindsay B, et al. Nasal residence of insulin containing lyophilised nasal insert formulations, using γ scintigraphy. Eur J Pharm Sci 31:25-31, 2007.
46. Moller W, Schuschnig U, Celik G, et al. Topical drug delivery in chronic rhinosinusitis patients before and after sinus surgery using pulsating aerosols. PLoS One 8:e74991, 2013.
47. Shah SA, Dickens CJ, Ward DJ, et al. Design of experiments to optimize an in vitro cast to predict human nasal drug deposition. J Aerosol Med Pulm Drug Deliv 27:21-29, 2014.
48. Liu X, Doub WH, and Guo C. Assessment of the influence factors on nasal spray droplet velocity using phase-Doppler anemometry (PDA). AAPS PharmSciTech 12:337-343, 2011.
49. Dayal P, Shaik MS, and Singh M. Evaluation of different parameters that affect droplet-size distribution from nasal sprays using the Malvern Spraytec. J Pharm Sci 93:1725-1742, 2004.
50. Harris AS, Nilsson IM, Wagner ZG, and Alkner U. Intranasal administration of peptides: nasal deposition, biological response, and absorption of desmopressin. J Pharm Sci 75:1085-1088,1986.
51. Bateman ND, Whymark AD, Clifton NJ, and Woolford TJ. A study of intranasal distribution of azelastine hydrochloride aqueous nasal spray with different spray techniques. Clin Otolaryngol Allied Sci 27:327-330, 2002.
52. Emanuel IA, Blaiss MS, Meltzer EO, et al. Nasal deposition of ciclesonide nasal aerosol and mometasone aqueous nasal spray in allergic rhinitis patients. Am J Rhinol Allergy 28:117-121,2014.
53. Le Guellec S, Le Pennec D, Gatier S, et al. Validation of anatomical models to study aerosol deposition in human nasal cavities. Pharm Res 31:228-237, 2014.
54. Costantino HR, Illum L, Brandt G, et al. Intranasal delivery: physicochemical and therapeutic aspects. Int J Pharm 337:1-24,2007.
55. Dhuria SV, Hanson LR, and Frey WH. Intranasal delivery to the central nervous system: Mechanisms and experimental considerations. J Pharm Sci 99:1654-1673, 2010.